(Press-News.org) A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson’s disease in which a patient’s stem cells are reprogrammed to replace dopamine cells in the brain damaged by the disease. The first-of-its-kind trial of an autologous stem cell transplant, based on research and technologies invented and validated preclinically at McLean Hospital’s Neuroregeneration Research Institute (NRI), has enrolled and treated three patients at Brigham and Women’s Hospital.
A total of six participants will be included in the Phase 1 trial that will track the patients for 12 months and beyond to determine the safety of the procedure and monitor for any improvements in Parkinson’s disease. Following the first 6 patients transplanted in the Phase 1 study, the researchers hope to expand and recruit more patients as part of Phase 2A study.
This novel therapeutic approach for treating Parkinson’s disease incorporates the use of stem cells derived from a patient’s own blood that had been converted into induced pluripotent stem cells (iPSCs). These cells are then reprogrammed to turn into specific midbrain dopaminergic neurons ready for transplantation. The autologous transplantation approach of using a person’s own cells circumvents the requirement for immunosuppressive treatments, which are necessary when cells from other donors are used.
Cell replacement for Parkinson’s disease replaces the dopamine neurons lost to degeneration and can restore dopaminergic function in the brain, providing a completely new treatment modality compared to the currently available treatments. The NRI’s founding director, Ole Isacson, Dr Med Sci, who is also a professor of neurology (neuroscience) at Harvard Medical School and Mass General Brigham, has pioneered work in cell therapy for Parkinson’s disease over the past 30 years and laid the foundation for this clinical trial.
“Seeing this transformational new patient cell-based replacement of their own dopamine neurons come to fruition — from the very basic science breakthroughs in our lab to be completely translated into a clinical application for patient’s suffering from Parkinson’s disease — is very gratifying,” said Isacson. “We believe this approach may open up a new treatment paradigm and lead to the development of many additional cell therapies to restore damaged brain systems and replace degenerated brain cells in other diseases.”
Under Isacson’s leadership, the NRI at McLean has developed and patented autologous cell-based restoration in Parkinson’s disease with a pioneering preclinical publication in 2002 using stem cells and the first preclinical demonstration of effective human iPS cell-derived dopamine neuron use in 2010. In 2015, the NRI team, led by Isacson and Penny Hallett, PhD, co-director of the NRI at McLean and associate professor of psychiatry at Harvard Medical School, provided the first evidence of long-term safety and benefits of autologous stem cell therapy in a highly relevant Parkinson’s disease non-human primate animal model.
The NRI received official authorization from the U.S. Food and Drug Administration (FDA) on August 23, 2023, approving its Investigational New Drug (IND) application for a phase 1 clinical trial to test this unique, autologous dopamine neuron cell therapy.
Following this FDA approval for the phase 1 clinical trial, the NRI’s innovative preclinical work was translated into the clinic with the first patient treated on September 9, 2024. This collaboration includes NRI investigators James Schumacher, MD, and Oliver Cooper, PhD, and colleagues in the Neurology (Michael Hayes, MD) and Neurosurgery (John Rolston, MD, PhD, principal investigator of the Phase 1 trial) Departments at Brigham and Women’s Hospital. Isacson is not directly involved in the clinical trial because he is the innovator patent holder of the technology and also a co-founder of Oryon Cell Therapies, which has the license to this technology. The trial is directed by Hallett and colleagues within the Mass General Brigham healthcare system and its Harvard Medical School-affiliated institutions.
“It is extraordinary to witness that investigators at our institution can bring new treatments to patients through the entire process of laboratory “bench to bedside,” and it inspires many investigators to similarly pursue their scientific and medical insights to reach patients in need,” said Kerry Ressler MD, PhD, chief scientific officer at McLean Hospital.
The Phase 1 open-label clinical trial will be the first such trial to test blood-derived autologous iPSC-derived dopamine neurons in patients with Parkinson’s disease and is funded by the National Institute of Health’s National Institute of Neurological Disorders and Stroke (NINDS). The NINDS awarded the highly competitive Cooperative Research to Enable and Advance Translational Enterprises for Biologics (CREATE Bio) grant for this work in 2020.
People seeking more information in the trial can email: neurosurgerycrc@bwh.harvard.edu
For More Information:
McLean Hospital Receives Coveted NIH Grant to Clinically Study Autologous Stem Cell Therapy for Parkinson’s Disease
Patient-derived stem cells could improve drug research for Parkinson’s
Funding: The study was supported by a NINDS CREATE Bio grant (U01NS109463).
The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Disclosure: Isacson has co-founded a company (Oryon Cell Therapies) which has licensed the patents and know-how for developing autologous cell therapies for Parkinson’s disease. Isacson’s interests were reviewed and are managed by McLean Hospital and Mass General Brigham in accordance with their conflict of interest polices.
###
About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.
END
Rocky Mountain spotted fever is a bacterial infection spread by biting ticks to humans and dogs. Found on every continent except Antarctica, the infectious disease has been spreading since the early 2000s, most notably in Mexico and Brazil. Of the cases reported, more than half of infected people and dogs die.
A paper led by the University of California, Davis, highlights one of the most effective but often missing solutions to surviving this preventable, deadly disease: awareness. Most fatal cases stem from delays in diagnosis and treatment.
“The No. 1 thing that prevents human death from Rocky Mountain spotted fever is for everyone at high risk to know ...
The prestigious journal Advanced Materials recently published a groundbreaking study introducing a new method for monitoring molecular processes deep within tissue. Developed at the Technion - Israel Institute of Technology, the innovation is expected to accelerate key advancements in personalized medicine, cancer diagnosis, and early disease detection. The research was led by Prof. Hossam Haick, postdoctoral fellow Dr. Arnab Maity, and Ph.D. student Vivian Darsa Maidantchik from the Wolfson Faculty of Chemical Engineering at the Technion. The study also involved Dr. Dalit Barkan, research assistant Dr. Keren ...
(Boston)—Sun Lee, MD, MSc, assistant professor of medicine at Boston University Chobanian & Avedisian School of Medicine, has been awarded an American Association of Clinical Endocrinology (AACE) Rising Star in Endocrinology Award.
The honor is presented to a physician who is within 10 years of completing their endocrine fellowship and has demonstrated actionable outcomes in outstanding leadership, teamwork and/or innovation in support of AACE’s mission to elevate clinical endocrinology ...
The Center for Stress, Resilience and Personal Growth at Mount Sinai—a first-of-its-kind initiative launched in April 2020 at the height of the COVID-19 pandemic to address its psychosocial impact on Mount Sinai Health System’s workforce—is now offering confidential behavioral health treatment services to New Yorkers generally.
A team of clinical psychologists, psychiatrists, and licensed clinical social workers from the Center is now available to individuals 18 years and older who are interested in and could benefit from behavioral health treatment. Clinical services include cognitive behavioral therapy, ...
(Boston)—More than 120 million Americans suffer from diabetes or pre-diabetes. Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer, and TNBC patients with obesity-driven diabetes often have worse outcomes.
A new study by researchers from Boston University Chobanian & Avedisian School of Medicine helps explain why this happens and suggests a potential way to improve treatment for these patients.
At present, oncologists do not consider patients with breast cancer and obesity-driven diabetes differently in any significant way from patients with breast cancer who are otherwise healthy.
The new study, "Insulin Resistance Increases ...
Two main manufacturers dominate the EV (electric vehicle) market: Tesla, which is most popular in Europe and North America, and BYD, which leads the Chinese EV market. However, both manufacturers have released limited data about their batteries, so the mechanical structure and characteristics of these battery cells has remained mysterious. To compare the batteries used by each manufacturer and better understand how EV batteries function overall, a team of researchers took one of each apart.
The results publish on March 6 in the Cell Press journal Cell Reports Physical Science and show that Tesla’s batteries prioritize high-energy density and performance, ...
Researchers at UC San Francisco have enabled a man who is paralyzed to control a robotic arm through a device that relays signals from his brain to a computer.
He was able to grasp, move and drop objects just by imagining himself performing the actions.
The device, known as a brain-computer interface (BCI), worked for a record 7 months without needing to be adjusted. Until now, such devices have only worked for a day or two.
The BCI relies on an AI model that can adjust to the small changes ...
Ice may be present a few centimetres below the Moon’s surface in more areas of the lunar polar regions than was previously thought due to large, yet highly localised, variations in surface temperatures. The results, published in Communications Earth & Environment, are derived from direct measurements taken at the lunar surface in 2023 by the Indian Chandrayaan-3 mission.
Future long-term exploration (or habitation) of the Moon will likely depend on the availability of ice to provide water, with the likelihood of ice formation in a ...
UCSF researchers are the first to demonstrate that the approach works for the patients who need it the most.
Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers at UCSF has found.
The strategy could also help stop the spread of HIV by keeping more patients from being infectious.
In 2021, federal regulators approved the first long-acting antiretroviral (LA-ART) injectable, which is a combination of long-acting cabotegravir and ...
Multidrug-resistant bacteria pose a major threat to human health. Manipulation of bacterial genes at the transcriptional level is a potential strategy to fight antibiotic-resistant bacterial infections by silencing their resistance genes. However, siRNAs have not been applied to regulate bacterial genes due to the lack of RNAi regulatory machinery, i.e., RNA-induced silencing complexes (RISCs), in bacteria. In addition, efficient methods for delivering siRNAs to bacteria in vivo are not currently available. In this study, ...
